CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FiercePharma
Original article

{"a":[{"_":"Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis","$":{"href":"/pharma/xpovio-mulligan-endometrial-cancer-comes-short-karyopharm-presses-myelofibrosis","hreflang":"en"}}]}

Data ReadoutnegativeXpovioXpovioNegative
AI Analysis

Summary

Karyopharm reported negative trial data for Xpovio in endometrial cancer but plans to continue advancing the XPO1 inhibitor in myelofibrosis despite investor disappointment from a previous March dataset.

Outcome Details

Xpovio failed to meet expectations in endometrial cancer indication

Importance:6/10
Sentiment:
-0.60
oncologyclinical_trial_failuredrug_developmentXPO1_inhibitor
Related Companies

Read the original article

Published by FiercePharma on July 31, 2026 9:36 AM

Read Original